Compare RYAAY & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAAY | ONC |
|---|---|---|
| Founded | 1985 | 2010 |
| Country | Ireland | Switzerland |
| Employees | 25952 | 12000 |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1B | 33.5B |
| IPO Year | N/A | N/A |
| Metric | RYAAY | ONC |
|---|---|---|
| Price | $61.38 | $283.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $78.00 | ★ $386.70 |
| AVG Volume (30 Days) | ★ 1.4M | 233.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.97 | $759.19 |
| Revenue Next Year | $5.33 | $14.51 |
| P/E Ratio | ★ $12.60 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.52 | $196.53 |
| 52 Week High | $74.24 | $385.22 |
| Indicator | RYAAY | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 37.96 | 29.62 |
| Support Level | $60.63 | $234.09 |
| Resistance Level | $63.05 | $284.51 |
| Average True Range (ATR) | 1.68 | 8.91 |
| MACD | -0.26 | -4.35 |
| Stochastic Oscillator | 9.24 | 1.56 |
Ryanair is Europe's largest low-cost airline, known for its extensive network and highly efficient business model. Operating over 3,600 flights daily across 240-plus destinations in 40 countries, Ryanair has built its success on offering affordable air travel while maintaining tight control over costs. The airline primarily uses Boeing 737 aircraft, including the newer 737 8-200 "Gamechanger" variant, which simplifies operations and reduces expenses. Ryanair focuses on high passenger volume, ancillary revenue, and operational efficiency, ensuring its position as a leading airline in Europe.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.